The contemporary psychiatric, neuropharmacological, and public health landscape across the United Kingdom, Germany, Sweden, New Zealand, Dubai, Australia, and the Netherlands is undergoing a profound structural evolution regarding rapid-acting psychoactive substances. As clinical investigators, public health authorities, and academic scholars evaluate innovative therapeutic models for treatment-resistant psychological conditions, researchers increasingly analyze compounds that challenge traditional […]